Thomas Marjot
Overview
Explore the profile of Thomas Marjot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
1998
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Hayat U, Moon A, Gangwani M, Hasan F, Marjot T, Barritt 4th A, et al.
JGH Open
. 2024 Dec;
8(12):e70064.
PMID: 39618959
Background: Patients with decompensated cirrhosis have a higher risk of hospitalization, ICU admission, and death from COVID-19. The impact of demographics on these outcomes remains uncertain. Methods: The SECURE-Liver and...
3.
Perez-Campuzano V, Rautou P, Marjot T, Praktiknjo M, Alvarado-Tapias E, Turco L, et al.
JHEP Rep
. 2024 Nov;
6(12):101191.
PMID: 39583091
Background & Aims: Patients with vascular liver diseases (VLD) are at higher risk of both severe courses of COVID-19 disease and thromboembolic events. The impact of SARS-CoV-2 vaccination in patients...
4.
Marjot T, Dhanda A
Nat Rev Gastroenterol Hepatol
. 2024 Oct;
22(1):3-4.
PMID: 39455889
No abstract available.
5.
Westcott F, Nagarajan S, Parry S, Savic D, Green C, Marjot T, et al.
Eur J Endocrinol
. 2024 Oct;
191(4):463-472.
PMID: 39353069
Objective: Fasting hyperglycemia and hypertriglyceridemia are characteristic of insulin resistance (IR) and rodent work has suggested this may be due to selective hepatic IR, defined by increased hepatic gluconeogenesis and...
6.
Colosimo S, Miller H, Koutoukidis D, Marjot T, Tan G, Harman D, et al.
Diabetes Res Clin Pract
. 2024 Aug;
217:111820.
PMID: 39147101
Objectives: Currently, non-invasive scoring systems to stage the severity of non-alcoholic fatty liver disease (NAFLD) do not consider markers of glucose control (glycated haemoglobin, HbA1c); this study aimed to define...
7.
Shah S, Barrado-Martin Y, Marjot T, Tomlinson J, Kiparoglou V
Cureus
. 2024 Apr;
16(3):e56038.
PMID: 38606249
Citizen science is a participatory science approach in which members of the public (citizens) collaborate with scientists and professional researchers and become involved in research and innovation activities, resulting in...
8.
Brennan P, Tavabie O, Li W, Marjot T, Corless L, Fallowfield J, et al.
Lancet Gastroenterol Hepatol
. 2024 Mar;
9(6):577-582.
PMID: 38428439
The American, European, and Latin American liver societies have proposed a change in the nomenclature we use to describe alcohol-related liver disease and non-alcoholic fatty liver disease. Additionally, a term...
9.
Maidstone R, Rutter M, Marjot T, Ray D, Baxter M
Endocr Connect
. 2023 Dec;
13(2).
PMID: 38055788
Background And Aims: Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common liver disease worldwide. Modern lifestyles have been linked to this rise in prevalence with changes in...
10.
Murray S, Pose E, Wittner M, Londono M, Schaub G, Cook J, et al.
J Hepatol
. 2023 Oct;
80(1):109-123.
PMID: 37863203
Background & Aims: Comparative assessments of immunogenicity following different COVID-19 vaccines in patients with distinct liver diseases are lacking. SARS-CoV-2-specific T-cell and antibody responses were evaluated longitudinally after one to...